Performance status

What it is

Performance status is a clinical rating of how well a person functions in daily life, often scored from 0 to 5. In cancer care, it summarises how active a person is, how much help they need, and whether they are well enough for treatments such as chemotherapy, radiation, surgery, or clinical trials. Doctors use it because functional ability often predicts treatment tolerance, complications, and survival better than age alone.

The two most used scales are the ECOG Performance Status and the Karnofsky Performance Status (KPS). ECOG is simpler and runs from 0 to 5, while KPS runs from 100 to 0 in steps of 10. A lower ECOG score or a higher KPS score means better function.

Scale	Best function	Worst function	What it describes
ECOG	0	5	Ability to work, walk, self-care, and time in bed/chair
Karnofsky (KPS)	100	0	Ability to carry on normal activity and need for assistance

A commonly used ECOG guide is:

1. ECOG 0: Fully active, no restriction in usual activities.
2. ECOG 1: Restricted in strenuous activity, but ambulatory and able to do light work.
3. ECOG 2: Ambulatory and capable of self-care, but unable to work; up and about more than 50% of waking hours.
4. ECOG 3: Limited self-care; in bed or a chair more than 50% of waking hours.
5. ECOG 4: Completely disabled; totally confined to bed or chair.
6. ECOG 5: Dead.

In India, performance status is routinely recorded in oncology clinics and tumour boards because it helps decide whether standard-dose treatment, modified treatment, supportive care, or palliative care is the safest option.

How it works

Performance status is not a lab test or scan. It is a structured clinical judgment based on symptoms and day-to-day function. The clinician asks about walking, bathing, dressing, eating, working, and time spent resting in bed or a chair. Some teams also consider weight loss, pain, breathlessness, frailty, and other illnesses, although these are not formally part of the basic ECOG score.

The reason performance status matters is practical. Cancer treatment places stress on the body. A person who is fully active usually has more physiologic reserve than someone who is bedbound or needs help with self-care. Because of this, performance status is often linked to:

• likelihood of completing treatment
• risk of severe side effects
• need for dose reduction or treatment delay
• hospital admission risk
• overall prognosis

KPS and ECOG broadly map to each other. For example, ECOG 0 is roughly similar to KPS 90-100, while ECOG 3 is roughly similar to KPS 30-50. The mapping is not exact, so clinicians usually stick to one scale within a service.

Evidence and uses

Performance status is one of the most established prognostic tools in oncology. Studies across many cancers show that worse performance status is associated with poorer survival and lower tolerance of systemic therapy. It is also built into many clinical trial eligibility criteria, where patients with ECOG 0-1 are often preferred, though some trials include ECOG 2.

Common uses include:

• Treatment planning: deciding whether a patient is fit for curative-intent treatment, standard-dose therapy, reduced-intensity therapy, or supportive care alone.
• Prognosis: helping estimate likely outcomes alongside stage, tumour biology, age, comorbidities, and lab results.
• Clinical trials: setting eligibility and stratifying patients so study groups are comparable.
• Communication: giving the care team a shared shorthand for functional ability.
• Palliative care: identifying patients who may need symptom-focused care, rehabilitation, nutrition support, or home-based assistance.

That said, performance status should not be used in isolation. A fit older adult may have ECOG 1 and tolerate treatment well, while a younger person with severe weight loss, organ dysfunction, or multiple illnesses may still be at high risk even with a similar score. Modern oncology increasingly combines performance status with frailty assessment, comorbidity review, symptom burden, and patient-reported outcomes.

Diagnosis / how it's measured

Performance status is measured during a clinical assessment, not diagnosed as a disease. The score may change over time, so it is often recorded at diagnosis, before each treatment cycle, at hospital admission, and when the treatment plan changes.

A clinician may ask questions such as:

• Are you able to walk around the house or outside?
• Can you bathe, dress, and eat without help?
• Are you working or doing household tasks?
• How much of the day do you spend in bed or sitting?
• Have symptoms like pain, breathlessness, weakness, or fatigue reduced your activity?

Important limitations in measurement include subjectivity and variation between observers. Two clinicians may score the same patient slightly differently. Research has shown that physician-rated performance status can be biased and may miss issues such as cognitive decline, frailty, depression, or social barriers to activity. For this reason, some centres add geriatric assessment, rehabilitation review, or patient-reported questionnaires.

When to see a clinician

Ask your cancer team about performance status if you notice a clear drop in daily function. Examples include spending much more time in bed, needing new help with bathing or dressing, becoming unable to walk short distances, or stopping usual work because of weakness or symptoms.

A sudden decline can signal infection, dehydration, anaemia, uncontrolled pain, medication side effects, blood clots, spinal cord compression, brain metastases, or progression of cancer. These problems may be treatable, and the performance status score can improve if the cause is addressed.

Families should also tell the team if the clinic score does not match what they see at home. A brief clinic visit can miss how much support a person really needs over a full day.

Limitations and open questions

Performance status is useful, but it is a blunt tool. It is unidimensional, meaning it reduces complex health status to a single number. It does not directly measure frailty, nutrition, cognition, mental health, symptom severity, or social support.

Evidence also shows that performance status is partly subjective. Inter-observer agreement is imperfect, especially in the middle ranges such as ECOG 1 versus 2. That matters because treatment decisions and trial eligibility may change at those cutoffs.

Another limitation is that poor performance status can come from different causes. One patient may have low function because of advanced cancer, while another may be limited by arthritis, stroke, or a reversible infection. The same score does not always mean the same prognosis.

Current research is exploring whether performance status should be supplemented by frailty tools, wearable activity data, patient-reported outcomes, and more formal geriatric assessment. Evidence suggests these added measures may improve prediction of treatment tolerance, but no single replacement has fully displaced ECOG or KPS in routine practice.